Zaprinast, a phosphodiesterase 5 inhibitor, overcomes sexual dysfunction produced by fluoxetine, a selective serotonin reuptake inhibitor in hamsters.
A high incidence of sexual dysfunction among women is reported in the clinical literature. Little experimental investigation has been initiated on the ability of phosphodiesterase (PDE) inhibitors to overcome deficits in sexual functioning because of selective serotonin reuptake inhibitors (SSRIs). The effects of fluoxetine, an SSRI, and zaprinast, a PDE-5 inhibitor, on the lateral displacement response (used as a measure of sensitivity to reproductively relevant stimuli) of hamsters in behavioral estrus were investigated. In Experiment 1, hamsters that were maximally sensitive to reproductively relevant stimuli because they were at the peak of behavioral estrus were administered fluoxetine (10 mg/kg, i.p.); they had significantly decreased lateral displacement responses compared to vehicle-administered hamsters. In Experiment 2, hamsters that were relatively less sensitive to sexual stimuli because they were at the termination of behavioral estrus were administered zaprinast (3 mg/kg; i.p.); they had significantly enhanced lateral displacement responses compared to responses seen following vehicle administration. In Experiment 3, fluoxetine-induced deficits in the lateral displacement of hamsters at the peak of behavioral estrus were overcome by the coadministration of zaprinast. These data confirm previous findings that sexual dysfunction can be induced by SSRIs and extend the current knowledge to suggest that administration of a PDE-5 inhibitor can override SSRI-induced deficits in sexual functioning.
Frye
Cheryl A
CA
Department of Psychology, The University of Albany, SUNY, Albany, NY 12222, USA. cafrye@cnsunix.albany.edu
Rhodes
Madeline E
ME
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000818:Animals; D006224:Cricetinae; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D005260:Female; D005473:Fluoxetine / Q000037:antagonists & inhibitors / Q000633:toxicity*; D008297:Male; D008647:Mesocricetus; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011688:Purinones / Q000494:pharmacology / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000037:antagonists & inhibitors / Q000633:toxicity; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000188:drug therapy* / Q000201:enzymology
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D005473:Fluoxetine; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D011688:Purinones; D017367:Selective Serotonin Reuptake Inhibitors; C011145:zaprinast